Blog Reduction Apr 23, 2013 It Sounds like a Great Idea, but how do we Apply “Reduction” to Toxicology Studies? NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy. Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines? How to Design a Successful Preclinical Program for Cellular Therapeutics Feb 14, 2012 Many cell therapeutics are now in clinical use, but how do they make it from the “bench” to clinical trials? In this article, we’ll consider the challenges. Non-Ocular Compounds May Call for Ocular Endpoints Jan 30, 2012 Should we include ocular endpoints in the preclinical development of products not targeted to the eye?
Reduction Apr 23, 2013 It Sounds like a Great Idea, but how do we Apply “Reduction” to Toxicology Studies?
NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy.
Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines?
How to Design a Successful Preclinical Program for Cellular Therapeutics Feb 14, 2012 Many cell therapeutics are now in clinical use, but how do they make it from the “bench” to clinical trials? In this article, we’ll consider the challenges.
Non-Ocular Compounds May Call for Ocular Endpoints Jan 30, 2012 Should we include ocular endpoints in the preclinical development of products not targeted to the eye?
